Alirocumab

Therapeutic indications

Alirocumab is indicated for:

Primary heterozygous familial hypercholesterolaemia, primary non-familial hypercholesterolaemia, mixed dyslipidaemia

Irrespective of gender only Adults (18 years old or older)

Alirocumab is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

The effect of alirocumab on cardiovascular morbidity and mortality has not yet been determined.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Subcutaneous - 75-150 mg once every 2 weeks

Treatment 2: Subcutaneous - 150-300 mg once every 4 weeks

Established atherosclerotic cardiovascular disease

Irrespective of gender only Adults (18 years old or older)

Alirocumab is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:

  • in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Subcutaneous - 75-150 mg once every 2 weeks

Treatment 2: Subcutaneous - 150-300 mg once every 4 weeks

Medication Recommendation

Receive personalized medication regimen for every patient case

Ask the Reasoner

Related medicines

Summary of product characteristics (SPC) 2022: PRALUENT Solution for injection

Previous: Overview
Next: Precautions